new version V2017

Eribulin nontaxane microtubule dynamics inhibitor

ER-86526 - ER 086526 - ER086526 - ER-086526 - B-1793 - B 1793 - NSC-707389 - NSC707389 - NSC 707389 - Halaven - E-7389 - E 7389 - B-1939 - B 1939      

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

advanced breast cancer (metastatic)

EMBRACE (Cortes), 2011eribulintreatment of physician Risk of bias ConclusiveNCT00388726
Vahdat, 2013eribulinixabepilone Exploratory - NCT00879086
Trial 301 (Kaufman), 2015eribulincapecitabine Risk of bias NegativeNCT00337103
NCT02037529 ongoing eribulinpaclitaxel Risk of bias - NCT02037529
SCRI BRE 197 ongoing eribulin+cyclophosphamidedocetaxel+cyclophosphamide - NCT01527487
2014-0857 ongoing eribulin+gemcitabinepaclitaxel+gemcitabine Exploratory - NCT02263495
E7389-C086-304 ongoing eribulinvinorelbine Exploratory - NCT02225470